全文获取类型
收费全文 | 22147篇 |
免费 | 1848篇 |
国内免费 | 1045篇 |
专业分类
耳鼻咽喉 | 296篇 |
儿科学 | 522篇 |
妇产科学 | 238篇 |
基础医学 | 2351篇 |
口腔科学 | 488篇 |
临床医学 | 2290篇 |
内科学 | 3998篇 |
皮肤病学 | 391篇 |
神经病学 | 1237篇 |
特种医学 | 818篇 |
外国民族医学 | 3篇 |
外科学 | 2142篇 |
综合类 | 3064篇 |
一般理论 | 3篇 |
预防医学 | 1895篇 |
眼科学 | 668篇 |
药学 | 2122篇 |
15篇 | |
中国医学 | 1042篇 |
肿瘤学 | 1457篇 |
出版年
2024年 | 28篇 |
2023年 | 212篇 |
2022年 | 349篇 |
2021年 | 840篇 |
2020年 | 606篇 |
2019年 | 603篇 |
2018年 | 790篇 |
2017年 | 591篇 |
2016年 | 594篇 |
2015年 | 840篇 |
2014年 | 1041篇 |
2013年 | 1099篇 |
2012年 | 1568篇 |
2011年 | 1695篇 |
2010年 | 1124篇 |
2009年 | 864篇 |
2008年 | 1195篇 |
2007年 | 1246篇 |
2006年 | 1094篇 |
2005年 | 1093篇 |
2004年 | 1059篇 |
2003年 | 1149篇 |
2002年 | 1079篇 |
2001年 | 856篇 |
2000年 | 745篇 |
1999年 | 542篇 |
1998年 | 197篇 |
1997年 | 229篇 |
1996年 | 202篇 |
1995年 | 146篇 |
1994年 | 112篇 |
1993年 | 84篇 |
1992年 | 179篇 |
1991年 | 158篇 |
1990年 | 119篇 |
1989年 | 134篇 |
1988年 | 101篇 |
1987年 | 93篇 |
1986年 | 77篇 |
1985年 | 58篇 |
1984年 | 39篇 |
1983年 | 25篇 |
1982年 | 15篇 |
1981年 | 11篇 |
1980年 | 11篇 |
1979年 | 16篇 |
1977年 | 12篇 |
1973年 | 9篇 |
1970年 | 9篇 |
1965年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
1.
2.
3.
4.
骨碎补是历代临床常用中药,具有疗伤止痛、补肾强骨、消风祛斑等功效。其主要含黄酮、苯丙素、三萜、酚酸及其苷等类化学成分,现代研究表明骨碎补具有抗骨质疏松、促进骨折愈合、促软骨再生、护牙健齿、保护肾功能、抗炎、防治中毒性耳聋、降血脂等多种生物活性,开发前景广阔。本文对近年来骨碎补的化学成分、药理作用及临床应用研究进行综述,以期为骨碎补的进一步深入系统的研究和开发利用提供依据。 相似文献
5.
Maria Gonzalez-Cao Cristina Carrera Juan Francisco Rodriguez Moreno Pedro Rodríguez-Jiménez Mónica Antoñanzas Basa Rosa Feltes Ochoa Teresa Puertolas Eva Muñoz-Couselo José Luis Manzano Ivan Marquez-Rodas Juan Martín-Liberal Ainara Soria Pilar Lopez Criado Almudena Garcia-Castaño Aram Boada Pablo Ayala de Miguel Susana Puig Guillermo Crespo Alfonso Berrocal 《Journal of the American Academy of Dermatology》2021,84(5):1412-1415
6.
7.
8.
Ana M. Gómez Angelica Imitola Diana Henao Maira García-Jaramillo Marga Giménez Clara Viñals Bruno Grassi Mariana Torres Isabella Zuluaga Oscar Mauricio Muñoz Martin Rondón Fabián León-Vargas Ignacio Conget 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):267-272
Background and aimsDespite using sensor-augmented pump therapy (SAPT) with predictive low-glucose management (PLGM), hypoglycemia is still an issue in patients with type 1 Diabetes (T1D). Our aim was to determine factors associated with clinically significant hypoglycemia (<54 mg/dl) in persons with T1D treated with PLGM-SAPT.Methodology: This is a multicentric prospective real-life study performed in Colombia, Chile and Spain. Patients with T1D treated with PLGM-SAPT, using sensor ≥70% of time, were included. Data regarding pump and sensor use patterns and carbohydrate intake from 28 consecutive days were collected. A bivariate and multivariate Poisson regression analysis was carried out, to evaluate the association between the number of events of <54 mg/dl with the clinical variables and patterns of sensor and pump use.Results188 subjects were included (41 ± 13.8 years-old, 23 ± 12 years disease duration, A1c 7.2% ± 0.9). The median of events <54 mg/dl was four events/patient/month (IQR 1–10), 77% of these events occurred during day time. Multivariate analysis showed that the number of events of hypoglycemia were higher in patients with previous severe hypoglycemia (IRR1.38; 95% CI 1.19–1.61; p < 0.001), high glycemic variability defined as Coefficient of Variation (CV%) > 36% (IRR 2.09; 95%CI 1.79–2.45; p < 0.001) and hypoglycemia unawareness. A protector effect was identified for adequate sensor calibration (IRR 0.77; 95%CI 0.66–0.90; p:0.001), and the use of bolus wizard >60% (IRR 0.74; 95%CI 0.58–0.95; p:0.017).ConclusionIn spite of using advanced SAPT, clinically significant hypoglycemia is still a non-negligible risk. Only the identification and intervention of modifiable factors could help to prevent and reduce hypoglycemia in clinical practice. 相似文献
9.
José A. Lorente Pablo Cardinal-Fernández Diego Muñoz Fernando Frutos-Vivar Arnaud W. Thille Carlos Jaramillo Aida Ballén-Barragán José M. Rodríguez Oscar Peñuelas Guillermo Ortiz José Blanco Bruno Valle Pinheiro Nicolás Nin María del Carmen Marin Andrés Esteban Taylor B. Thompson 《Intensive care medicine》2015,41(11):1921-1930
10.
CD2AP inhibits metastasis in gastric cancer by promoting cellular adhesion and cytoskeleton assembly
Wangkai Xie Chao Chen Zheng Han Jingjing Huang Xin Liu Hongjun Chen Teming Zhang Sian Chen Chenbin Chen Mingdong Lu Xian Shen Xiangyang Xue 《Molecular carcinogenesis》2020,59(4):339-352
Diffuse gastric cancer (DGC) is a lethal malignancy lacking effective systemic therapy. Among the most provocative recent results in DGC has been that the alter of the cellular cytoskeleton and intercellular adhesion. CD2-associated protein (CD2AP) is one of the critical proteins regulating cytoskeleton assembly and intercellular adhesion. However, no study has investigated the expression and biological significance of CD2AP in gastric cancer (GC) to date. Therefore, the aim of our study was to explore if the expression of CD2AP is associated with any clinical features of GC and to elucidate the underlying mechanism. Immunohistochemistry of 620 patient tissue samples indicated that the expression of CD2AP is downregulated in DGC. Moreover, a low CD2AP level was indicative of poor patient prognosis. In vitro, forced expression of CD2AP caused a significant decrease in the migration and invasion of GC cells, whereas depletion of CD2AP had the opposite effect. Immunofluorescence analysis indicated that CD2AP promoted cellular adhesion and influenced cell cytoskeleton assembly via interaction with the F-actin capping protein CAPZA1. Overall, the upregulation of CD2AP could attenuate GC metastasis, suggesting CD2AP as a novel biomarker for the prognosis and treatment of patients with GC. 相似文献